VCNX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs...

Stats
Today's Volume	3 373.00
Average Volume	11 443.00
Market Cap	7.89M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.131 (2.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Smith Ernest S.	Buy	1 341	Stock Option (Right to Buy)
2024-03-21	Sanchez Jill	Buy	805	Stock Option (Right to Buy)
2024-03-21	Evans Elizabeth E.	Buy	1 341	Stock Option (Right to Buy)
2024-03-21	Zauderer Maurice	Buy	1 877	Stock Option (Right to Buy)
2024-05-10	Yanni Barbara	Buy	10 108	Stock Option (Right to Buy)

INSIDER POWER
99.87
Last 100 transactions
Buy: 38 167 240 \| Sell: 15 944

Vaccinex Inc Correlation

10 Most Positive Correlations
EZGO	0.873
RPTX	0.872
Z	0.849
ZG	0.849
INMD	0.848
ALLR	0.847
ADBE	0.845
SHLS	0.845
LULU	0.844
CBRL	0.843

10 Most Negative Correlations
GALT	-0.879
SBNY	-0.876
ENTX	-0.872
PPC	-0.849
STAA	-0.847
RZLT	-0.846
PPTA	-0.845
CDXC	-0.844
CURI	-0.837
VITL	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaccinex Inc Financials

Annual	2023
Revenue:	$570 000
Gross Profit:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2023
Revenue:	$570 000
Gross Profit:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2022
Revenue:	$100 000
Gross Profit:	$-107 000 (-107.00 %)
EPS:	$-97.59

FY	2021
Revenue:	$900 000
Gross Profit:	$900 000 (100.00 %)
EPS:	$-1.191

Financial Reports:

No articles found.

Vaccinex Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Realtime updates for Vaccinex Inc [VCNX]

Upcoming Earnings Alert

Vaccinex Inc Options Data

Calls

Puts